Clinical trials
Carcinoma clinical trials
Below are recruiting carcinoma clinical trials, each written for real people, not researchers. We’re tracking 3,160 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05741073Recruiting
Study of European registry data for advanced skin cancers
This study uses information from a European registry to learn how real-world treatments work for advanced non-melanoma skin cancers. It may help doctors improve care in the future, especially for people who have had surgery and radiation or who cannot have curative treatments.
BrusselsAges 18 years+ - NCT05740995Recruiting
New pre-op treatment for esophageal cancer using immunotherapy plus chemo
This trial studies giving immunotherapy (anti–PD-1) together with chemotherapy before surgery for certain locally advanced esophageal squamous cell cancer. The goal is to improve how well the tumor responds before and after the operation.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05746208RecruitingPhase 2
Lenvatinib plus pembrolizumab for advanced grade 3 NET tumors
This trial studies lenvatinib plus pembrolizumab to treat well-differentiated grade 3 neuroendocrine tumors (NETs) that cannot be fully removed by surgery or are locally advanced. It aims to shrink the tumor or slow its growth after the disease shows progression.
San Francisco, CaliforniaAges 18 years+ - NCT05746325Recruiting
Tumor-pulse device for spinal cancer fluid spread
This trial tests whether Tumor Treating Fields (a non-surgical device that delivers treatment signals to cancer cells through the scalp/skin) can help people whose breast or lung cancer has spread into the fluid around the spine and brain. It focuses on people who have cancer cells found in spinal fluid and can safely use the device most of the day.
Jacksonville, FloridaAges 18 years+ - NCT05753839Recruiting
Testing surgery plus immunotherapy for metastatic kidney cancer
This trial studies whether removing the kidney tumor (cytoreductive nephrectomy) before treatment can improve outcomes for people with metastatic clear-cell kidney cancer. All participants are expected to receive standard immunotherapy (nivolumab plus ipilimumab), and the study focuses on the role of surgery in the “immuno-oncology era.”
SeoulAges 18 years+ - NCT05768178RecruitingPhase 2/Phase 3
Vemurafenib plus cobimetinib for BRAF-mutant cancers
This trial tests whether combining two targeted cancer medicines—vemurafenib and cobimetinib—can treat adults whose tumors have a specific “BRAF V600” mutation. You may be screened with blood tests and a tissue biopsy before starting treatment.
BelfastAges 18 years+ - NCT05770531RecruitingPhase 2
Blood test guides chemo changes for metastatic breast cancer
This Phase 2 study uses a blood test that looks for “circulating tumor DNA” to help decide if standard chemotherapy should be changed. It aims to see whether this approach improves how well treatment works for certain metastatic (stage IV) breast cancers.
Nashville, TennesseeAges 18 years+ - NCT05772208RecruitingPhase 3
New treatment plan for nasopharyngeal cancer after EBV DNA stays detectable
This Phase 3 trial tests a stronger treatment approach for people with locally advanced nasopharyngeal cancer whose EBV “DNA” (a cancer-related virus signal in blood) does not go away after one cycle of chemotherapy. It may help improve outcomes by changing treatment based on how the cancer responds early.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05774483Recruiting
Check nodes in early mouth cancer using a biopsy or planned neck surgery
This trial studies two ways to check whether early oral cavity cancer has spread to nearby neck lymph nodes. It compares sentinel node biopsy versus limited elective neck dissection to see which approach is more useful for people with node-negative tongue or inner-cheek cancers.
Mumbai, MaharashtraAges 18–80 - NCT05775939Recruiting
PET/CT scan study to track heart damage from cancer radiation
This study uses a special scan (PET/CT) to look for early heart (cardiac) injury caused by radiation treatment for lung or esophageal cancer. If you may be at higher heart risk from your planned radiation dose, the scan may help researchers better measure that damage over time.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05791149Recruiting
Saliva test to help diagnose oral cavity cancer
This study looks for changes in saliva (epigenetic biomarkers) that may help doctors diagnose squamous cell carcinoma in the mouth. You may be asked for saliva samples and usual clinical checks to see whether the test can help with diagnosis, especially before surgery.
Amiens, PicardieAges 18 years+ - NCT05798793RecruitingPhase 3
Chemo plus anti–PD-1 before surgery for mouth cancer
This trial studies whether giving anti–PD-1 immunotherapy together with chemotherapy before surgery can improve outcomes for people with locally advanced, operable oral squamous cell carcinoma. It aims to shrink the cancer and make surgery more effective by treating both the tumor and the immune response.
Shenzhen, GuangdongAges 18–70 - NCT05802186Recruiting
AI-guided radiation plan for lung cancer tumors
This study uses an AI tool to help plan how doctors deliver focused radiation to lung tumors. It may help make radiation targeting more precise and support treatment safety for people with primary or limited metastatic lung cancer.
Chicago, IllinoisAges 18 years+ - NCT05803382RecruitingPhase 1
Adding a new drug to capecitabine for metastatic colorectal cancer
This Phase 1 study tests a new anti-cancer drug (ZEN003694) added to the usual chemotherapy capecitabine. It is for adults with colorectal cancer (and possibly other cancers) that has spread or cannot be removed and has continued despite prior standard treatment.
Irvine, CaliforniaAges 18 years+ - NCT05805371RecruitingPhase 1
PSCA CAR-T cells with or without radiation for prostate cancer
This Phase 1 study tests a prostate cancer treatment made of PSCA-targeted CAR-T cells, with or without radiation, to help control advanced prostate cancer. It aims to find a safe treatment approach and see how well it works in people whose cancer has PSCA.
Duarte, CaliforniaAges 18 years+ - NCT05809869RecruitingPhase 2
Immunotherapy plus liver radiation for metastatic liver cancer
This trial tests whether combining an immunotherapy drug with a special type of liver radiation (yttrium-90) can control metastatic hepatocellular carcinoma (liver cancer that has spread). It may help by boosting your immune system and shrinking liver tumors at the same time.
Hong KongAges 18 years+ - NCT05824975RecruitingPhase 1/Phase 2
Test drug GI-102 alone or with cancer medicines
This Phase 1/2 study tests whether GI-102 is safe and can help shrink advanced solid tumors. It also looks at GI-102 used with standard cancer treatments like pembrolizumab or trastuzumab deruxtecan (T-DXd).
Scottsdale, ArizonaAges 18 years+ - NCT05828446Recruiting
Improving liver cancer screening for people at risk
This study looks at ways to improve screening for liver cancer in adults with long-term liver disease. It may help catch liver cancer earlier, which can make treatment easier.
Lausanne, Canton of VaudAges 18 years+ - NCT05832827RecruitingPhase 2
First treatment combo for thymic cancer using pembrolizumab plus drugs
This Phase 2 study tests a first (initial) treatment combination of pembrolizumab with three other drugs (carboplatin, paclitaxel, and lenvatinib) for advanced or recurrent thymic carcinoma. It aims to shrink tumors and improve control of the cancer when standard chemotherapy has not yet been tried for your situation.
Chūō, TokyoAges 18 years+ - NCT05833594Recruiting
Immunonutrition plus chemoradiation for unresectable esophageal cancer
This trial studies whether adding an “immunonutrition” nutrition plan to standard chemoradiation can improve outcomes for people with locally advanced, unresectable esophageal squamous cell cancer. It may help the treatment work better by supporting the immune system during therapy.
HefeiAges 18–85 - NCT05842174RecruitingPhase 1/Phase 2
Checking a new treatment approach for liver cancer needing TACE
This early-stage trial studies a new strategy for hepatocellular carcinoma (a type of liver cancer) in people who are planned to receive TACE, a procedure that delivers treatment through the liver’s blood supply. It aims to test whether targeting a specific cell survival process can improve how well the treatment works and is tolerated.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05844046RecruitingPhase 2
Triple drug treatment for advanced liver cancer that can’t be removed
This Phase 2 trial tests three medicines together (durvalumab, tremelimumab, and bevacizumab) to treat non-surgical (non-resectable) liver cancer. It may help shrink tumors and slow disease progression by boosting the immune system and blocking tumor blood supply.
MunichAges 18 years+ - NCT05856643RecruitingEarly Phase 1
Study drug for ovarian cancer after prior treatment failure
This early-phase study tests SZ011 in people with ovarian epithelial cancer that has come back or did not respond to standard first treatment. You may qualify if your tumor shows a specific marker (mesothelin) and your health tests are strong enough to safely receive the study drug.
Shantou, GuangdongAges 18–80 - NCT05862168RecruitingPhase 2
Tislelizumab with chemotherapy before surgery for oral cancer
This trial studies giving tislelizumab (an immune treatment) plus chemotherapy before surgery to shrink and treat locally advanced oral squamous cell cancer. It aims to improve tumor response and outcomes, while checking safety.
HangzhouAges 18–75
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for carcinoma?
- Yes. Clin2 currently lists 3,160 recruiting carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.